2560 Baseline serum clusterin level in patients with poor prognostic features was associated with response to custirsen treatment: Results from the phase 3 SYNERGY trial of docetaxel +/- custirsen. (September 2015) - De Bono, J.; Higano, C.; Blumenstein, B.; Feyerabend, S.; Gravis, G.; Ferrero, J.M.; Jacobs, C.; Chi, K.